Galera reports third quarter 2023 financial results and recent corporate updates

Fda confirms need for new trial for avasopasem; greco trials with rucosopasem to be discontinued company evaluating potential strategic options to optimize shareholder value malvern, pa., nov. 14, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended september 30, 2023 and provided recent corporate updates.
GRTX Ratings Summary
GRTX Quant Ranking